Search PubMed⌕ Search

Biomedical subjects

I Persson

Publications and source records attributed to I Persson.

At least 181 records · Page 10Linked to original sources
PubMed1984

Breast cancer as a risk factor for other primary malignant diseases. A nationwide cohort study.

A cohort comprising 11,452 women and based on virtually all cases of first incidence of breast cancer in Sweden in 1964-67 was followed for 13-16 completed years--corresponding to 94,078 person-years of observation--for the occurrence of subsequent primary tumors other than in the breast. A slight excess in the total number of second malignant diseases (695 observed vs. 633.7 expected; relative risk (RR) = 1.10) was possibly partly due to a higher autopsy rate with more frequent detection of preclinical cancers in the cohort than in the background population. A significant risk increase was confirmed for endometrial cancer after the age of 70 years (RR = 2.4; 95% confidence limits = 1.6-3.5) but not for ovarian cancer (RR = 1.2) or tumors of the large bowel (RR = 1.2), rectum (RR = 1.1), or any other site. It was concluded that: 1) so many subgroups were analyzed in this study that the significant association with endometrial cancer might be due to the play of chance alone and, therefore, needs further confirmation, 2) there is no common genetically linked susceptibility to primary cancer of the breast and that of other sites, 3) the hypothesis that cancers of the breast and large bowel share major etiologic factors was not supported, and 4) it is unlikely that secondary cancers significantly contribute to the late excess mortality in breast cancer patients.

Adult↗
PubMed1983

Cohort study of oestrogen treatment and the risk of endometrial cancer: evaluation of method and its applicability.

A Swedish study of the risk of endometrial cancer associated with oestrogen treatment was started in 1977. A prospective design was chosen and a cohort of 23,233 women receiving oestrogen medication was collected over a three-year period. Cohort members were recruited on the basis of prescription forms for oestrogens produced by all 120 pharmacies in a defined geographical region, resulting in comprehensive coverage of that region. A questionnaire study of a random sample (1/30) of the cohort permitted mapping of confounding factors, estimation of drug compliance and detailed characterization of oestrogen and progestagen exposures. Efficient follow-up of the cohort members was achieved by linkage of identity numbers of cohort members and those of all incident cases of endometrial cancer in the region. The expected outcome was calculated on the basis of accumulated person-years of observation in the entire cohort - and in subgroups - and age-specific incidence rates of endometrial cancer in the reference population. The present design may be generally useful for post-marketing studies of the association between drug use and side-effects.

Adult↗
PubMed1983

Practice and patterns of estrogen treatment in climacteric women in a Swedish population. A descriptive epidemiological study. Part I.

A cohort of 23 233 women to whom estrogens had been prescribed and constituting a total material from a defined Swedish population was recruited for the purpose of conducting a prospective follow-up study of endometrial cancer. Their exposure to estrogens was studied in detail by means of a comprehensive questionnaire, which was mailed to 735 randomly selected women from the cohort and answered by 89%. This paper describes the practice of estrogen prescribing in the population and the patterns of exposure of the cohort, as estimated from the sample. Our results indicated: restrictive usage of estrogens with a marked downward secular trend in the frequency of prescriptions; short duration of treatment and frequent temporary interruptions; predominant choice of estradiol valerate compounds; preference for cyclic administration and low-strength tablets; acceptance of recommended dose levels; and adherence to a few, established indications for treatment. When compared with data from a large number of other epidemiological studies, the risk of endometrial cancer in this cohort is likely to be lower.

Adult↗
PubMed1983

Characteristics of estrogen-treated women. A descriptive epidemiological study of a Swedish population. Part II.

A cohort of 23 233 women who had received estrogen prescriptions was recruited for a prospective study of estrogen therapy and the associated risk of endometrial cancer. For a detailed study, a comprehensive questionnaire was mailed to 735 randomly sampled cohort members, and 89 per cent of them responded. Estrogen exposure and its implications were described in a preceding paper (part I). The present paper reports the distribution in the cohort sample of personal features known to be risk factors for endometrial cancer. A comparison with results from various materials derived from population-based surveys and case-control studies implied that the cohort members might have a lower proportion of nulliparity (infertility) and a somewhat higher prevalence of hypertension. Differences in the distributions of age at menarche or menopause, weight, height and prevalence of diabetes were according to these comparisons slight and probably without clinical significance. It was concluded that the prevalence of risk factors for endometrial cancer other than estrogen exposure was not higher in the cohort than in the background population. Moreover, approximately one-fifth of the estrogen takers had been freed of their risk through hysterectomies.

Adolescent↗
PubMed1978

Treatment of hypertension in the elderly with pindolol and clopamide.

After a 2-week washout period, 30 elderly hypertensive patients were treated with pindolol (a beta-adrenergic blocker) for 3 weeks. In 13 patients the reduction in blood pressure was satisfactory and treatment with pindolol was continued for another 4 weeks. In 17 patients the subsequent treatment was supplemented with clopamide (a diuretic) for 4 weeks; in 6 the results were satisfactory. Side effects were few and mild.

Aged↗
PubMed1976

Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.

Thirty patients suffering from essential hypertension were treated successively with placebo, hydralazine alone, and pindolol (Viskén) combined with hydralazine. As compared to placebo hydralazine brought about a statistically significant reduction in blood pressure and an increase in pulse rate; palpitation was an irritating side-effect. Combining hydralazine and pindolol caused an additional fall in blood pressure (2 p less than 0.001) and the pulse rate decreased (2 p less than 0.001). This combination treatment had a favourable effect on the palpitation and angina pectoris also.

Adult↗
PubMed1975

Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.

Thirty patients suffering from essential hypertension were treated successively with placebo, hydralazine alone, and pindolol (Visken) combined with hydralazine. Hydralazine caused a statistically significant reduction in blood pressure and an increase in pulse rate as compared with the placebo: palpitations were an irritating side-effect. The combination of hydralazine and pindolol resulted in an additional fall in blood pressure (p less than 0.001) and the pulse rate decreased (2 p less than 0.001). The combined treatment also had a favourable effect on palpitations and angina pectoris.

Adult↗
PubMed1975

The HL-A7 histocompatibility antigen in sarcoidosis in relation to tuberculin sensitivity.

Eighty cases of sarcoidosis have been investigated. In all except eight patients a histological verification of the diagnosis was obtained by mediastinoscopy or liver biopsy. The HL-A7 antigen was not increased in the entire group. However, in the group of patients with a negative sensitivity to tuberculin after the appearance of the disease there was a significant increase compared with controls. In the patients with a positive reaction, there was a complete absence of HL-A7. The HL-A system therefore does not seem to influence the liability to contract sarcoidosis, but once this condition has developed HL-A7 positives are more likely to lose cellular immunity to tuberculin and to reveal symptoms.

Adolescent↗